Core Viewpoint - BeiYikang (920199) experienced a trading halt today, reaching a daily limit increase of 29.98%, with a turnover rate of 12.94% and a total transaction amount of 213 million yuan [2] Trading Activity - The stock was listed on the Longhu list due to its daily price fluctuation limit, with a net buying amount of 12.91 million yuan from brokerage seats [2] - The top five brokerage seats accounted for a total transaction amount of 86.39 million yuan, with a buying amount of 49.65 million yuan and a selling amount of 36.74 million yuan, resulting in a net buying of 12.91 million yuan [2] - The largest buying brokerage was CITIC Securities Co., Ltd. Nanchang Beijing East Road Securities Brokerage, with a buying amount of 12.11 million yuan, while the largest selling brokerage was China Galaxy Securities Co., Ltd. Xingtai Metallurgical North Road Securities Brokerage, with a selling amount of 9.60 million yuan [2] Historical Performance - Over the past six months, BeiYikang has appeared on the Longhu list six times, with an average price increase of 1.04% the day after being listed and an average decline of 3.32% in the following five days [2]

Summary of Key Points Core Viewpoint The trading volume and value of stocks on the Beijing Stock Exchange (BSE) showed a significant increase on January 5, with a total trading volume of 803 million shares and a total trading value of 21.188 billion yuan, marking an increase of 474 million yuan compared to the previous trading day. The majority of stocks experienced price increases, indicating a positive market sentiment. Trading Performance - The total trading volume on the BSE reached 803 million shares, with a trading value of 21.188 billion yuan, an increase of 474 million yuan from the previous day [1] - A total of 226 stocks closed higher, accounting for 79.02% of the tradable stocks, with notable gainers including KaiDe Quartz (up 22.36%), JinHao Medical (up 20.03%), and HengDong Light (up 12.94%) [1] - Conversely, 57 stocks closed lower, with TianMing Technology, JiaXian Co., and LiFang Holdings experiencing the largest declines of 15.03%, 10.33%, and 8.46% respectively [1] Active Stocks - 56 stocks had a trading value exceeding 100 million yuan, with HengDong Light leading at 1.909 billion yuan, followed by XingTu Measurement Control at 736 million yuan and KaiDe Quartz at 477 million yuan [1] - The trading activity was robust, with 23 stocks having a turnover rate exceeding 10%, and 5 stocks exceeding 20% [1] - The stocks with the highest turnover rates included DaPeng Industrial (28.25%), HengDong Light (27.83%), and ChenGuang Medical (24.13%) [1] Notable Stock Data - The closing prices and performance of key stocks included: - HengDong Light: 348.99 yuan, up 12.94%, turnover rate 27.83%, trading value 1.909 billion yuan [1] - XingTu Measurement Control: 90.50 yuan, up 7.10%, turnover rate 19.74%, trading value 736 million yuan [1] - KaiDe Quartz: 47.28 yuan, up 22.36%, turnover rate 18.24%, trading value 477 million yuan [1]

Core Viewpoint - On January 5, 2026, Beiyikang (920199) experienced a significant stock price increase of 29.98%, leading to its appearance on the trading leaderboard with a trading volume of 4.7824 million shares and a transaction value of 213 million yuan [1][2]. Group 1: Trading Performance - Beiyikang's closing price reached 44.96 yuan, marking a notable increase in its stock value [1]. - The total trading volume for the day was 4.7824 million shares, with a total transaction amount of 213 million yuan [1]. - The top buying seat was from CITIC Jiantou Securities Co., Ltd., Nanchang Beijing East Road Securities Business Department, which purchased shares worth approximately 12.11 million yuan [2]. Group 2: Trading Participants - The second largest buyer was CITIC Jiantou Securities Co., Ltd., Huzhou People's Road Securities Business Department, with a purchase amount of approximately 12.05 million yuan [2]. - The largest selling seat was from China Galaxy Securities Co., Ltd., Xingtai Metallurgy North Road Securities Business Department, which sold shares worth approximately 9.60 million yuan [2]. - Other notable selling participants included Guotai Junan Securities Co., Ltd. and Xinda Securities Co., Ltd., with significant sell amounts recorded [2].

Market Overview - The Shanghai Composite Index closed at 4023.42 points, above the six-month moving average, with an increase of 1.38% [1] - The total trading volume of A-shares reached 30,483.30 billion yuan [1] Stocks Above Six-Month Moving Average - A total of 313 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - BeiYikang (证券代: 920199) with a deviation rate of 19.09% and a price increase of 29.98% [1] - *ST Huike (证券代: 300561) with a deviation rate of 18.68% and a price increase of 19.99% [1] - Weisi Medical (证券代: 688580) with a deviation rate of 18.24% and a price increase of 20.00% [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the six-month moving average include: - Garden Holdings (证券代: 300430) with a deviation rate of 13.12% and a price increase of 19.98% [1] - Hongya CNC (证券代: 301033) with a deviation rate of 13.22% and a price increase of 20.00% [1] - Zhongke Sanhuan (证券代: 688314) with a deviation rate of 12.97% and a price increase of 19.99% [1]

Core Viewpoint - The A-share market experienced a significant surge on January 5, 2026, driven by the brain-computer interface (BCI) sector, with the index rising over 12% and multiple stocks hitting their daily limit up [1] Group 1: Market Performance - On the opening day of the A-share market, stocks related to brain-computer interfaces saw a collective rally, with stocks like BeiYikang (920199.BJ) hitting a 30% limit up and others such as Botao Bio (688767.SH) and Sanbo Neuroscience (301293.SZ) reaching 20% limit up [1] - A total of 11 stocks in the BCI sector experienced a 20% limit up, indicating strong investor interest and market momentum [1] Group 2: Technological Developments - The surge in the BCI sector was catalyzed by news of mass production of BCI devices by Elon Musk's company, Neuralink, expected to begin in 2026, which includes advancements in surgical procedures [1] - Neuralink's device will feature electrodes that can penetrate the dura mater without removal, marking a significant technological breakthrough [1] Group 3: Domestic Developments - In China, several companies are emerging that parallel Neuralink's technological approach, with Guotai Junan Securities declaring 2025 as the year for clinical trials of invasive and semi-invasive BCIs [2] - Companies like Borui Kang have completed clinical trials, with expectations for regulatory approval in 2026, while other firms are also making progress in BCI technology [2] Group 4: Market Projections - Open Source Securities predicts that BCI technology will redefine human-robot interaction and is expected to commercialize by 2026, expanding from medical applications to AI and robotics [3] - The global BCI market is projected to grow to approximately $12.4 billion by 2034, with a CAGR of 17% from 2025 to 2034, indicating strong future growth potential [3]

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 12 月 25 日 2.会议召开地点：四川千里倍益康医疗科技股份有限公司会议室 3.会议召开方式：现场投票、网络投票 4.会议召集人：董事会 证券代码：920199 证券简称：倍益康 公告编号：2025-128 四川千里倍益康医疗科技股份有限公司 2025 年第四次临时股东会决议公告 5.会议主持人：董事长张文先生 6.召开情况合法合规的说明： 本次股东会的召集及召开时间、方式、召集人及主持人符合《公司法》《公 司章程》的规定，审议事项合法、完备。 （二）会议出席情况 出席和授权出席本次股东会的股东共 10 人，持有表决权的股份总数 50,458,066 股，占公司有表决权股份总数的 74.08%。 其中通过网络投票参与本次股东会的股东共 0 人，持有表决权的股份总数 0 股，占公司有表决权股份总数的 0%。 （三）公司需选择情形出席或列席股东会情况 1. 公司在任董事 8 人，出 ...

大成蓉（2025）法意字第 3302 号 北 京 大 成 （ 成 都 ） 律 师 事 务 所 关 于 四 川 千 里 倍 益 康 医 疗 科 技 股 份 有 限 公 司 2025 年 第 四 次 临 时 股 东 会 的 法律意见书 北 京 大 成 （ 成 都 ） 律 师 事 务 所 www.dentons.cn 四川省成都市高新区天府二街吉瑞五路 396 号金控时代广场 2 栋 邮编：610000 Building 2 of Financial Holding Times Square, No. 396 Jirui 5th Road,Tianfu 2nd Stree,High-tech Zone,Chengdu,China Tel: +8628-87039931 Fax: +8628-87036893 北京大成（成都）律师事务所 关于四川千里倍益康医疗科技股份有限公司 2025 年第四次临时股东会的法律意见书 致：四川千里倍益康医疗科技股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）《中华人民共 和国公司法》（以下简称"《公司法》"）《上市公司股东会规则》《上市公司 治理准则》《北京证券交 ...

Group 1 - The brain-computer interface (BCI) is recognized as a future industry in China's 14th Five-Year Plan, with policies aimed at fostering its development, including a target for core technology breakthroughs by 2027 and achieving global leadership by 2030 [3][12][16] - The global BCI market was valued at $1.5 billion in 2021 and is projected to reach $3.3 billion by 2027, while the domestic market is expected to grow from 3.2 billion yuan in 2024 to 4.6 billion yuan by 2026, reflecting an 18.81% year-on-year growth in 2024 [3][17][19] - Non-invasive BCIs dominate the market, accounting for 86% of the total, with medical applications being the primary focus, representing 56% of the downstream enterprises [18][23][25] Group 2 - The 2024 national pharmaceutical circulation market is projected to reach 2.947 trillion yuan, with the wholesale market accounting for 77.94% of total sales, and the retail market contributing 22.06% [4][40][46] - The pharmaceutical distribution industry is characterized by a continuous optimization of structure, enhanced professional service capabilities, and a growing focus on health services, driven by aging populations and increased health awareness [52][53] - The North Exchange has 11 listed companies related to pharmaceuticals, with significant profit margins reported, including companies like Deyuan Pharmaceutical and Xinghao Pharmaceutical, which have shown substantial growth in net profits [4][51][68] Group 3 - The North Exchange's pharmaceutical and biotechnology sector saw a weekly increase of 1.91%, with medical devices leading the growth at 6%, while 80.95% of the sector's stocks experienced an increase in market value [5][58][61] - Notable stock performances include Lude Medical and Beiyikang, which saw weekly increases of 20.61% and 10.46%, respectively, indicating strong market interest in these companies [5][67] - As of December 19, 2025, there are 13 pharmaceutical and biotechnology companies queued for listing on the North Exchange, with an average revenue of 382 million yuan and net profits exceeding 100 million yuan for several firms [68][69]

证券代码：920199 证券简称：倍益康 公告编号：2025-119 四川千里倍益康医疗科技股份有限公司 第四届董事会第四次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 12 月 8 日 2.会议召开地点：公司会议室 5.会议主持人：董事长张文 6.会议列席人员：高级管理人员、董事会秘书 7.召开情况合法合规的说明： 本次会议的召集、召开、议案审议程序等方面符合《公司法》等法律、行政 法规、部门规章、规范性文件和《公司章程》《董事会议事规则》的规定。 （二）会议出席情况 会议应出席董事 8 人，出席和授权出席董事 8 人。 3.会议召开方式：现场加通讯 4.发出董事会会议通知的时间和方式：2025 年 11 月 28 日以书面方式发出 自公司股东会审议通过之日起 12 个月内有效，授信期限内，授信额度可循环使 用。具体内容详见公司于 2025 年 12 月 10 日在北京证券交易所信息披露平台 （http://w ...

东莞证券股份有限公司 关于四川千里倍益康医疗科技股份有限公司 预计 2026 年日常性关联交易的核查意见 东莞证券股份有限公司（以下简称"东莞证券"或"保荐机构"）作为四川 千里倍益康医疗科技股份有限公司（以下简称"倍益康"或"公司"）向不特定 合格投资者公开发行股票并在北交所上市的保荐机构，根据《证券发行上市保荐 业务管理办法》《北京证券交易所上市公司持续监管办法（试行）》《北京证券 交易所证券发行上市保荐业务管理细则》《北京证券交易所股票上市规则》等有 关规定，对倍益康预计 2026 年日常性关联交易的事项进行了核查，具体情况如 下： 一、关联交易概述 根据公司生产经营情况，公司对 2026 年度可能发生的日常性关联交易进行 预计，具体情况如下： | 单位：万元 | | --- | | | | 预计 2026 | | 2025 年与关联 | | 预计金额与上年实 | | --- | --- | --- | --- | --- | --- | --- | | 关联交易类别 | 主要交易内容 | 年发生金额 | | 方实际发生金 | | 际发生金额差异较 | | | | | | 额 | | 大的原因 | | ...